CLDX — Celldex Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.45bn
- $2.02bn
- $6.88m
Annual cashflow statement for Celldex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.9 | -59.8 | -70.5 | -112 | -141 |
| Depreciation | |||||
| Non-Cash Items | 3.93 | 15.7 | 7.59 | 9.6 | 17.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.32 | -0.299 | -1.05 | -3.9 | 13.5 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -46.4 | -40.4 | -60.9 | -104 | -107 |
| Capital Expenditures | -0.731 | -1.55 | -1.25 | -1.83 | -1.82 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 17.8 | -96.7 | -215 | 91.8 | -104 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 17.1 | -98.2 | -216 | 89.9 | -106 |
| Financing Cash Flow Items | 0.009 | 0.434 | 2.48 | 4.08 | 2.24 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.3 | 171 | 272 | 4.08 | 218 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.1 | 32.6 | -4.69 | -9.71 | 5.38 |